OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Other Events

ME Staff 8-k
-
0
OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Other Events

OPHTHOTECH CORPORATION (NASDAQ:OPHT) Files An 8-K Other Events
Item 9.01. Other Events.

On August22, 2018, Ophthotech Corporation (the “Company”) issued a press release announcing that the preclinical anatomical and functional proof-of-concept study results related to the Company’s adeno-associated virus gene therapy candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa were published in Proceedings of the National Academy of Sciences. A copy of this press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

99.1 Press Release dated August22, 2018


Ophthotech Corp. Exhibit
EX-99.1 2 a18-21018_1ex99d1.htm EX-99.1 Exhibit 99.1       Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences   – Preclinical Proof-of-Concept Results in a Large Animal Model Published Online Ahead of Print in PNAS –   New York,…
To view the full exhibit click here

About OPHTHOTECH CORPORATION (NASDAQ:OPHT)

Ophthotech Corporation is a biopharmaceutical company. The Company specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration (AMD). Its advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs. It is also developing its product candidate Zimura for the treatment of patients with geographic atrophy, a form of dry AMD, in combination with VEGF therapy for the treatment of polypoidal choroidal vasculopathy (PCV). Fovista is being tested in Phase III clinical development. In addition, it has initiated additional clinical trials to evaluate the potential additional benefits of Fovista administered in combination with anti-VEGF drugs in wet AMD patients, known as Fovista Expansion Studies. Zimura has completed a small, multicenter, uncontrolled, open label Phase I/IIa clinical trial.